These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 28596160)

  • 21. The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes.
    Katz PM; Leiter LA
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S167-75. PubMed ID: 26654860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective.
    Madaan T; Akhtar M; Najmi AK
    Eur J Pharm Sci; 2016 Oct; 93():244-52. PubMed ID: 27531551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urinary Angiotensinogen and Renin Excretion are Associated with Chronic Kidney Disease.
    Juretzko A; Steinbach A; Hannemann A; Endlich K; Endlich N; Friedrich N; Lendeckel U; Stracke S; Rettig R
    Kidney Blood Press Res; 2017; 42(1):145-155. PubMed ID: 28395289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased urinary excretion of angiotensinogen is associated with risk of chronic kidney disease.
    Mills KT; Kobori H; Hamm LL; Alper AB; Khan IE; Rahman M; Navar LG; Liu Y; Browne GM; Batuman V; He J; Chen J
    Nephrol Dial Transplant; 2012 Aug; 27(8):3176-81. PubMed ID: 22399491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats.
    Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
    J Pharm Pharmacol; 2014 Jul; 66(7):975-87. PubMed ID: 24533859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased urinary angiotensinogen is precedent to increased urinary albumin in patients with type 1 diabetes.
    Saito T; Urushihara M; Kotani Y; Kagami S; Kobori H
    Am J Med Sci; 2009 Dec; 338(6):478-80. PubMed ID: 19884815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urinary angiotensinogen increases in the absence of overt renal injury in high fat diet-induced type 2 diabetic mice.
    Reverte V; Gogulamudi VR; Rosales CB; Musial DC; Gonsalez SR; Parra-Vitela AJ; Galeas-Pena M; Sure VN; Visniauskas B; Lindsey SH; Katakam PVG; Prieto MC
    J Diabetes Complications; 2020 Feb; 34(2):107448. PubMed ID: 31761419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Promising cardiovascular and blood pressure effects of the SGLT2 inhibitors: a new class of antidiabetic drugs.
    Chrysant SG
    Drugs Today (Barc); 2017 Mar; 53(3):191-202. PubMed ID: 28447076
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reply to 'Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes' by Yoshimoto
    León Jiménez D; Pérez Temprano R; Ruiz Hueso R; Lopéz Chozas JM; Miramontes González JP
    J Investig Med; 2018 Feb; 66(2):e4. PubMed ID: 29030417
    [No Abstract]   [Full Text] [Related]  

  • 30. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
    Lee S
    Crit Pathw Cardiol; 2017 Sep; 16(3):93-95. PubMed ID: 28742644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Canagliflozin for the treatment of type 2 diabetes.
    Babu A
    Drugs Today (Barc); 2013 Jun; 49(6):363-76. PubMed ID: 23807940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.
    Jabbour SA
    Postgrad Med; 2014 Jan; 126(1):111-7. PubMed ID: 24393758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
    Nicolle LE; Capuano G; Ways K; Usiskin K
    Curr Med Res Opin; 2012 Jul; 28(7):1167-71. PubMed ID: 22548646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the effects of insulin and SGLT2 inhibitor on the Renal Renin-Angiotensin system in type 1 diabetes mice.
    Miyata KN; Zhao S; Wu CH; Lo CS; Ghosh A; Chenier I; Filep JG; Ingelfinger JR; Zhang SL; Chan JSD
    Diabetes Res Clin Pract; 2020 Apr; 162():108107. PubMed ID: 32173417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor velagliflozin, a new drug with therapeutic potential to treat diabetes in cats.
    Hoenig M; Clark M; Schaeffer DJ; Reiche D
    J Vet Pharmacol Ther; 2018 Apr; 41(2):266-273. PubMed ID: 29139146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients.
    Mizushige T; Kobori H; Hitomi H; Nishijima Y; Tomoda F; Morimoto S; Kohno M; Nishiyama A
    Int J Mol Sci; 2016 Oct; 17(11):. PubMed ID: 27801805
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Relationship between Increases in Morning Spot Urinary Glucose Excretion and Decreases in HbA
    Kim SR; Lee YH; Kang ES; Cha BS; Lee BW
    Diabetes Ther; 2017 Jun; 8(3):601-609. PubMed ID: 28332143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome.
    Rahman A; Kittikulsuth W; Fujisawa Y; Sufiun A; Rafiq K; Hitomi H; Nakano D; Sohara E; Uchida S; Nishiyama A
    J Hypertens; 2016 May; 34(5):893-906. PubMed ID: 26982381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between urinary angiotensinogen and salt sensitivity of blood pressure in patients with IgA nephropathy.
    Konishi Y; Nishiyama A; Morikawa T; Kitabayashi C; Shibata M; Hamada M; Kishida M; Hitomi H; Kiyomoto H; Miyashita T; Mori N; Urushihara M; Kobori H; Imanishi M
    Hypertension; 2011 Aug; 58(2):205-11. PubMed ID: 21670416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urinary angiotensinogen excretion is associated with blood pressure in obese young adults.
    Sato E; Mori T; Satoh M; Fujiwara M; Nakamichi Y; Oba I; Ogawa S; Kinouchi Y; Sato H; Ito S; Hida W
    Clin Exp Hypertens; 2016; 38(2):203-8. PubMed ID: 26825581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.